Press "Enter" to skip to content

FDA expected to restrict use of two COVID-19 monoclonal antibody treatments

The Food and Drug Administration is expected to significantly restrict the use of a pair of monoclonal antibody treatments for COVID-19 because they are ineffective against the omicron variant, a senior administration health official confirmed.As a…
Source: The Hill

Be First to Comment

    Leave a Reply

    Your email address will not be published.